Funded Startups in Laguna Hills
Laguna Hills’ most recent disclosed rounds show a clear size outlier: Arthrosi Therapeutics’ $61M (2025-06-23) and Sonendo’s $63M (2022-09-23) sit at the t…
Laguna Hills’ most recent disclosed rounds show a clear size outlier: Arthrosi Therapeutics’ $61M (2025-06-23) and Sonendo’s $63M (2022-09-23) sit at the top end of the list, with the rest clustered between $2M and $35M (for example, Aureka Biotechnologies’ $35M on 2026-04-28; Sensible Care’s $2M on 2026-03-03). Sector concentration is also strong: 7 of the 10 entries are in Biotechnology, spanning multiple deal years from 2021-08-12 (PharmaCyte Biotech) through 2026-04-28 (Aureka Biotechnologies).
Timing is more clustered than the full range suggests. Several rounds cluster in 2025–2026 (Aureka Biotechnologies 2026-04-28 at $35M; Sensible Care 2026-03-03 at $2M; Adagio Medical 2025-10-15 at $19M; Arthrosi Therapeutics 2025-06-23 at $61M). Stage disclosures skew toward incomplete labels as well: 5 of 10 rows use “Series Unknown” (including Sensible Care 2026-03-03 at $2M), while the remaining entries include Series A and Post-IPO Equity classifications.
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed rounds look largest in the Laguna Hills list, and how far above the next tier do they sit?
Sonendo’s $63M (2022-09-23) is the highest disclosed amount, and it is followed closely by Arthrosi Therapeutics’ $61M (2025-06-23). The next-largest disclosed amounts are $35M (Aureka Biotechnologies, 2026-04-28) and $21M (Strike Acceptance, 2024-02-13), leaving a comparatively wide gap between the top pair and the rest.
Are there sector or stage patterns that repeat across multiple entries?
Biotechnology dominates the city list: 7 of 10 entries are Biotechnology (Aureka Biotechnologies; Arthrosi Therapeutics; Sonendo; Hallux; Prelude; Amberstone Biosciences; PharmaCyte Biotech). On stage labels, 5 of 10 rows are marked “Series Unknown” (e.g., Sensible Care $2M on 2026-03-03; Adagio Medical $19M on 2025-10-15; Strike Acceptance $21M on 2024-02-13).
How concentrated are deals in the most recent window covered by these rows?
Four entries fall within roughly the last two years of the list (2024-02-13 to 2026-04-28): Strike Acceptance $21M (2024-02-13), Adagio Medical $19M (2025-10-15), Sensible Care $2M (2026-03-03), and Aureka Biotechnologies $35M (2026-04-28). Those four sit alongside earlier clusters in 2022 (Sonendo $63M on 2022-09-23; Hallux $9M on 2022-04-13; Prelude $20M on 2022-03-22).
Is there an outlier entry by disclosed amount that would distort comparisons?
Yes. Sensible Care’s $2M (2026-03-03) is the smallest disclosed amount in the rows, well below other low-to-mid entries such as Hallux $9M (2022-04-13) and Amberstone Biosciences $12M (2022-01-03). This makes the spread between the smallest disclosed round and the top disclosed rounds (e.g., Sonendo $63M) unusually wide for the dataset shown.
Do the rounds suggest a recurring company-type mix: biotech-heavy with occasional non-biotech deals?
The mix is heavily biotech but not exclusively. Alongside the 7 Biotechnology entries, there are two other sector classifications—Health Care (Sensible Care $2M on 2026-03-03; Adagio Medical $19M on 2025-10-15) and Commerce and Shopping (Strike Acceptance $21M on 2024-02-13)—which means non-biotech appears intermittently rather than as a consistent sequence.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.